| Identification | Back Directory | [Name]
GSK547 | [CAS]
2226735-55-1 | [Synonyms]
RIP1I GSK547 CPD3508 RIP1 inhibitor 547 RIP1 inhibitor GSK547 (S)-6-(4-(5-(3,5-Difluorophenyl)-4,5-dihydro-1H-pyrazole-1-carbonyl)piperidin-1-yl)pyrimidine-4-carbonitrile 4-Pyrimidinecarbonitrile, 6-[4-[[(5S)-5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazol-1-yl]carbonyl]-1-piperidinyl]- | [Molecular Formula]
C20H18F2N6O | [MDL Number]
MFCD32062767 | [MOL File]
2226735-55-1.mol | [Molecular Weight]
396.39 |
| Chemical Properties | Back Directory | [Boiling point ]
578.3±60.0 °C(Predicted) | [density ]
1.43±0.1 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
DMSO:65.0(Max Conc. mg/mL);163.98(Max Conc. mM) | [form ]
Solid | [pka]
1.93±0.28(Predicted) | [color ]
White to off-white | [InChI]
InChI=1S/C20H18F2N6O/c21-15-7-14(8-16(22)9-15)18-1-4-26-28(18)20(29)13-2-5-27(6-3-13)19-10-17(11-23)24-12-25-19/h4,7-10,12-13,18H,1-3,5-6H2/t18-/m0/s1 | [InChIKey]
SJVGFKBLUYAEOK-SFHVURJKSA-N | [SMILES]
C1=NC(N2CCC(C(N3[C@H](C4=CC(F)=CC(F)=C4)CC=N3)=O)CC2)=CC(C#N)=N1 |
| Hazard Information | Back Directory | [Uses]
GSK547 (GSK'547) is a highly selective and potent inhibitor of receptor-interacting serine/threonine protein kinase 1 (RIPK1), inhibits macrophage-mediated adaptive immune tolerance in pancreatic cancer[1]. | [Biological Activity]
GSK'547 is a highly selective and potent inhibitor of RIP1 (RIPK1) with a 400-fold increase in oral exposure compared to GSK'963 in mouse pharmacokinetic studies. | [in vitro]
In vitro, treatment with GSK'547 directed bone marrow-derived macrophages to develop an immunogenic phenotype, with up-regulation of MHC-II, TNFa and IFNg expression, and decreased CD206, IL- 10 and TGFb expression. In addition, it also up-regulated STAT1 signaling and decreased STAT3, STAT5 and STAT6 signaling in bone marrow-derived macrophages. Macrophages treated with GSK'547 had stronger ability to capture antigens. | [in vivo]
Mice were given GSK'547 through food, the concentration of GSK'547 in vivo was stable within 24 hours, which was higher than the IC50 value in L929 cells. GSK'547 maintained high concentrations in vivo during the 6-week administration. GSK'547 was well tolerated with no obvious pathological features. In mice with in situ pancreatic ductal adenocarcinoma, It reduced tumor burden and prolonged survival compared to control and Nec-1s-treated groups. GSK'547 prevents established tumors and liver metastases. | [target]
| Target | Value | RIP1 () | table>[References]
[1] Wang W, et al. RIP1 Kinase Drives Macrophage-Mediated Adaptive Immune Tolerance in Pancreatic Cancer. Cancer Cell. 2018 Nov 12;34(5):757-774.e7. DOI:10.1016/j.ccell.2018.10.006 |
|
| Company Name: |
BOC Sciences
|
| Tel: |
16314854226 |
| Website: |
www.bocsci.com |
|
|
Tags:2226735-55-1
Related Product Information
|
|
1627856-64-7
1346572-63-1
1652591-81-5
1346547-00-9
1010411-21-8
929095-18-1
1628332-52-4
1622849-58-4
1616392-22-3
188591-46-0
1362154-70-8
|
岗巴县|
类乌齐县|
米林县|
林西县|
海宁市|
南涧|
荣昌县|
盱眙县|
定安县|
忻州市|
颍上县|
博罗县|
康定县|
岳池县|
合作市|
崇文区|
铁岭市|
明光市|
德清县|
徐汇区|
安陆市|
东明县|
洮南市|
灵璧县|
四子王旗|
凤凰县|
韶山市|
余姚市|
汾西县|
天柱县|
平舆县|
吉林省|
定西市|
庐江县|
白玉县|
承德市|
清远市|
吉木萨尔县|
金华市|
长垣县|
定陶县|
|